Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is based in New Haven, Connecticut.

Period	Debt/Equity
2019-12-31	0.10
2020-12-31	0.73
2021-12-31	1.25
2022-12-31	0.14
2023-12-31	0.08
2024-12-31	0.11
2025-12-31	0.06

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TRVI	$17.71	+2.91%	2.46M
3
4
5

Trevi Therapeutics Inc. (TRVI) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Trevi Therapeutics Inc. Data in Excel

More TRVI Financial Data